Navigation Links
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
Date:5/18/2009

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disease (IBD). The engagement will utilise PharmaVentures' transactions experience in the healthcare and investment business sectors.

Kappaproct, approved for Orphan Drug Designation in Europe, has recently successfully concluded its third clinical phase II trial for the treatment of Inflammatory Bowel Disease patients. Due to the highly positive interim results at both one and four weeks after dosing, this trial, which included 34 patients and was conducted as a multi-center study in Sweden and Russia, was concluded early. Kappaproct showed the same excellent safety profile as seen in previous trials.

Kappaproct is currently approved for clinical developmental use as a rectal, single-dose administration. Qualification of the compound for other routes of administration and multiple dosing is underway through an extended toxicology program.

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures is very pleased to be involved in bringing this groundbreaking technology to the market. InDex are leaders in the field of immunomodulation via Toll Like Receptors."

InDex will be presenting Phase II data at BIO on Wednesday 20th May. See also InDex's Press Release released today: http://www.indexpharmab.com/images/pdf/kappaproctmay2009.pdf

Visit PharmaVentures during BIO at booths 4209 & 4211 for further information on this and other licensing opportunities.

    For enquiries about this opportunity, please contact:
    Dr Adrian Dawkes
    Managing Consultant
    PharmaVentures
    adrian.dawkes@pharmaventures.com
    +44 (0) 1865 784 193

Notes to Editors:

A leading results driven organisation, PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored consulting and transaction advisory services to the Life Science industry, with additional deal making support provided through the PharmaDeals range of intelligence products which include analysis tools and reports.

For further information please contact:

    Fiona Bishop
    PharmaVentures
    +44 (0) 1865 784 187
    fiona.bishop@pharmaventures.com

InDex Pharmaceuticals AB ("InDex") is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its DIMS platform (DNA-based immunomodulatory sequence). DIMS drugs are developed to treat diseases within a variety of therapeutic areas, including inflammation and cancer. InDex has several proprietary DIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistant/dependent ulcerative colitis.

    Svante Rasmuson, CEO
    Phone: +46 (0)8 50 88 47 31
    Mobile: +46 (0)708 63 93 31
    E-Mail: svante.rasmuson@indexpharmab.com

    Oliver von Stein, CSO
    Phone: +46 (0)8 50 88 47 32
    Mobile: +46 (0)708 93 33 75
    E-Mail: oliver.stein@indexpharmab.com

www.indexpharmab.com


'/>"/>
SOURCE PharmaVentures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Standard & Poors Announces Changes to U.S. Index
2. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
3. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
4. Chindex International, Inc. Announces May Conference Participation
5. ICW Master Patient Index Passes HITSP Certification and IHE Tests
6. SXC Health Solutions Added to S&P/TSX Composite Index
7. HCD Research and Muhlenberg College Will Use an Index to Monitor Physicians and Consumers Perceptions of Health Care Reform
8. MIB Life Index Reports North American Life Insurance Activity up 1.1% in February
9. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
10. Molecular Oncology accepted into Thomson Reuters index
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, ... more than $100 billion in purchasing power, today announced ... and information. The Newsroom is the online ... industry trends, infographics, expert bios, news releases, slideshows and ... access to a wealth of resources at their fingertips, ...
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
Breaking Medicine Technology: